Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer

Most studies on CTCs have focused on isolating cells that express EpCAM. In this study, we emphasize the presence of EpCAM-negative and EpCAM<sup>low</sup> CTCs, in addition to EpCAM<sup>high</sup> CTCs, in early BC. We evaluated stem cell markers (CD44/CD24 and CD133) and EMT markers (N-cadherin) in each subpopulation. Our findings indicate that all stemness variants were present in both EpCAM<sup>high</sup> and EpCAM-negative CTCs, whereas only one variant of stemness (nonCD44+CD24-/CD133+) was observed among EpCAM<sup>low</sup> CTCs. Nearly all EpCAM<sup>high</sup> CTCs were represented by CD133+ stem cells. Notably, the hybrid EMT phenotype was more prevalent among EpCAM-negative CTCs. scRNA-seq of isolated CTCs and primary tumor partially confirmed this pattern. Therefore, further investigation is imperative to elucidate the prognostic significance of EpCAM-negative and EpCAM<sup>low</sup> CTCs.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2024-10-16
DOI
https://doi.org/10.3390/ijms252011109
Citations
10
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
2.83

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer

Е. Yu. Garbukov, Л. А. Таширева, Evgeny V. Denisov, М. А. Vostrikova et al.
10 citations
International Journal of Molecular Sciences
Cancer Cells and Metastasis
2.83
article

Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer

Е. Yu. Garbukov, Л. А. Таширева, Evgeny V. Denisov, М. А. Vostrikova, Anna Yu. Kalinchuk, М. V. Zavyalova, В. В. Алифанов, V. М. Perelmuter, O. E. Savelieva, Н. В. Чердынцева, Evgeniya S. Grigoryeva, Olga Bragina, Elena S. Andryuhova, Ivan A. Patskan
article en
10 citations

Abstract

Most studies on CTCs have focused on isolating cells that express EpCAM. In this study, we emphasize the presence of EpCAM-negative and EpCAM<sup>low</sup> CTCs, in addition to EpCAM<sup>high</sup> CTCs, in early BC. We evaluated stem cell markers (CD44/CD24 and CD133) and EMT markers (N-cadherin) in each subpopulation. Our findings indicate that all stemness variants were present in both EpCAM<sup>high</sup> and EpCAM-negative CTCs, whereas only one variant of stemness (nonCD44+CD24-/CD133+) was observed among EpCAM<sup>low</sup> CTCs. Nearly all EpCAM<sup>high</sup> CTCs were represented by CD133+ stem cells. Notably, the hybrid EMT phenotype was more prevalent among EpCAM-negative CTCs. scRNA-seq of isolated CTCs and primary tumor partially confirmed this pattern. Therefore, further investigation is imperative to elucidate the prognostic significance of EpCAM-negative and EpCAM<sup>low</sup> CTCs.

International Journal of Molecular SciencesVol. 25(20)
Russian Academy of Sciences (RU), Tomsk National Research Medical Center (RU)
Russian Science Foundation
Good health and well-being
Openalex Percentile: Top 8%
Cancer Cells and Metastasis
2.83
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.